ラトビア - ラトビア語 - Zāļu valsts aģentūra

gedeon richter plc., hungary - fentanils - tablete lietošanai zem mēles - 100 μg

ラトビア - ラトビア語 - Zāļu valsts aģentūra

gedeon richter plc., hungary - fentanils - tablete lietošanai zem mēles - 800 μg

ラトビア - ラトビア語 - Zāļu valsts aģentūra

merck sharp & dohme de españa s.a., spain - dezogestrels - apvalkotās tabletes - 75 mikrogrami

ラトビア - ラトビア語 - Zāļu valsts aģentūra

vedim, poland - cetirizīna dihidrohlorīds - pilieni iekšķīgai lietošanai, šķīdums - 10 mg/ml

ラトビア - ラトビア語 - Zāļu valsts aģentūra

ucb pharma, spain - cetirizīna dihidrohlorīds - pilieni iekšķīgai lietošanai, šķīdums - 10 mg/ml

ラトビア - ラトビア語 - Pārtikas un veterinārais dienests, Zemkopības ministrija

cits, tējas maisiņi

ラトビア - ラトビア語 - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

欧州連合 - ラトビア語 - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostatas audzēji - diagnostikas radiofarmaceitiskie preparāti - Šīs zāles ir paredzētas tikai diagnostikas vajadzībām. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

欧州連合 - ラトビア語 - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistiskā fibroze - other respiratory system products - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

欧州連合 - ラトビア語 - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistiskā fibroze - other respiratory system products - orkambi tabletes ir indicēts, lai ārstētu cistiskā fibroze (cf) pacientiem vecumā no 6 gadiem un vecākiem, kas ir homozygous par f508del cftr mutācija gēnu. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.